SMAD2

Overview

One-paragraph summary of the gene’s role and why it matters in cancer genomics.

Alterations observed in the corpus

  • Mutation classes (missense / truncating / fusion / amplification / deletion) with links to the papers that report them.
  • Identified among significantly mutated genes in 188 primary LUAD tumours (TSP cohort); TGF-beta pathway effector. PMID:18948947
  • Significantly mutated in TCGA colorectal cancer cohort (276 tumors); SMAD2 loss-of-function mutations identified in the TGF-beta signaling pathway PMID:22810696
  • Recurrent TGF-β pathway mutations in gastric cancer (TCGA); co-altered with SMAD4 in this pathway. PMID:25079317
  • Right-sided enrichment of mutations observed in metastatic colorectal cancer (mCRC) cohort. PMID:29316426

Cancer types (linked)

  • Per cancer type: prevalence, co-mutation patterns, clinical significance.

Co-occurrence and mutual exclusivity

  • Linked partner genes with the relationship and the paper(s) reporting it.

Therapeutic relevance

  • Drugs (linked) targeting this gene or its pathway, with the studies supporting them.

Open questions

  • Conflicts or unresolved findings across papers.

Sources

This page was processed by crosslinker on 2026-05-05. - PMID:18948947

This page was processed by crosslinker on 2026-05-05. - PMID:22810696

This page was processed by wiki-cli on 2026-05-06. - PMID:25079317

This page was processed by wiki-cli on 2026-05-11. - PMID:29316426

This page was processed by entity-page-writer on 2026-05-15.